(Translated by https://www.hiragana.jp/)
Arginine/lysine: Difference between revisions - Wikipedia Jump to content

Arginine/lysine: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Importing Wikidata short description: "Combination drug"
update infobox, links, templates
Line 1: Line 1:
{{Short description|Combination drug}}
{{Short description|Combination drug}}
{{One source|date=July 2020}}

{{Use American English|date=July 2020}}
{{Use American English|date=July 2020}}
{{Use dmy dates|date=July 2020}}
{{Use dmy dates|date=July 2020}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
{{Infobox drug
| drug_name =
| type = combo
| type = combo
| image =
| image =
Line 17: Line 15:
<!-- Combo data -->
<!-- Combo data -->
| component1 = Arginine
| component1 = Arginine
| class1 = Amino acid
| class1 = [[Amino acid]]
| component2 = Lysine
| component2 = Lysine
| class2 = Amino acid
| class2 = [[Amino acid]]


<!-- Clinical data -->
<!-- Clinical data -->
| pronounce =
| pronounce =
| tradename = LysaKare
| tradename = Lysakare
| Drugs.com =
| Drugs.com =
| MedlinePlus =
| MedlinePlus =
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU = yes
| DailyMedID =
| DailyMedID =
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AUえーゆー = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AUえーゆー = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AUえーゆー_comment =
| pregnancy_AUえーゆー_comment =
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_US_comment =
| pregnancy_category=
| pregnancy_category=
⚫
| routes_of_administration = [[Intravenous infusion]]
| dependency_liability =
| addiction_liability =
⚫
| routes_of_administration = Intravenous infusion
| ATCvet =
| ATC_prefix = V03
| ATC_prefix = V03
| ATC_suffix = AF11
| ATC_suffix = AF11
Line 54: Line 44:
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_NZ_comment =
| legal_UK = POM
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = <ref>{{cite web | title=Lysakare Summary of Product Characteristics (SmPC) | website=(emc) | date=2 May 2024 | url=https://www.medicines.org.uk/emc/product/12724/smpc | access-date=24 May 2024}}</ref>
| legal_UK_comment =
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment =
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU = Rx-only
| legal_EU_comment =
| legal_EU_comment = <ref name="LysaKare EPAR" />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_UN_comment =
Line 65: Line 55:


<!-- Identifiers -->
<!-- Identifiers -->

| CAS_number_Ref =
| CAS_number = 2447636-40-8
| CAS_number = 2447636-40-8
| PubChem =
| PubChem =
| IUPHAR_ligand =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID =
| ChemSpiderID =
| UNII_Ref =
| UNII =
| UNII =
| KEGG_Ref =
| KEGG = D12136
| KEGG = D12136
| ChEBI_Ref =
| ChEBI =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =
| ChEMBL =
| NIAID_ChemDB =
| NIAID_ChemDB =
Line 86: Line 70:
}}
}}


'''Arginine/lysine''', sold under the brand name '''LysaKare''', is a fixed-dose [[combination medication]] used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called [[DOTA-TATE#Lutetium Lu 177|lutetium (<sup>177</sup>Lu) oxodotreotide]].<ref name="LysaKare EPAR">{{cite web | title=LysaKare EPAR | website=[[European Medicines Agency]] (EMA) | date=24 May 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lysakare | access-date=22 July 2020}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> It contains <small>L</small>-[[arginine]] hydrochloride and <small>L</small>-[[lysine]] hydrochloride.<ref name="LysaKare EPAR" />
'''Arginine/lysine''', sold under the brand name '''Lysakare''', is a fixed-dose [[combination medication]] used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called [[DOTA-TATE#Lutetium Lu 177|lutetium (<sup>177</sup>Lu) oxodotreotide]].<ref name="LysaKare EPAR">{{cite web | title=Lysakare EPAR | website=[[European Medicines Agency]] (EMA) | date=24 May 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lysakare | access-date=22 July 2020}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> It contains <small>L</small>-[[arginine]] hydrochloride and <small>L</small>-[[lysine]] hydrochloride.<ref name="LysaKare EPAR" />


The most common side effects include nausea and vomiting.<ref name="LysaKare EPAR" /> Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.<ref name="LysaKare EPAR" /> Side effects with arginine/lysine are usually mild or moderate.<ref name="LysaKare EPAR" />
The most common side effects include nausea and vomiting.<ref name="LysaKare EPAR" /> Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.<ref name="LysaKare EPAR" /> Side effects with arginine/lysine are usually mild or moderate.<ref name="LysaKare EPAR" />
Line 95: Line 79:


== Medical uses ==
== Medical uses ==
Arginine/lysine is indicated for reduction of renal radiation exposure during [[peptide receptor radionuclide therapy]] (PRRT) with lutetium (<sup>177</sup>Lu) oxodotreotide in adults.<ref name="LysaKare EPAR" />
Arginine/lysine is [[indicated]] for reduction of renal radiation exposure during [[peptide receptor radionuclide therapy]] (PRRT) with lutetium (<sup>177</sup>Lu) oxodotreotide in adults.<ref name="LysaKare EPAR" />


== References ==
== References ==
{{Reflist}}
{{Reflist}}


{{Detoxifying agents for antineoplastic treatment}}
== External links ==
⚫
{{Portal bar | Medicine}}
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/rn/74-79-3 | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Arginine }}
{{Authority control}}
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/lysine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Lysine }}

⚫
{{Portal bar | Medicine}}


{{DEFAULTSORT:Arginine Lysine}}
{{DEFAULTSORT:Arginine Lysine}}

Revision as of 06:29, 24 May 2024

Arginine/lysine
Combination of
ArginineAmino acid
LysineAmino acid
Clinical data
Trade namesLysakare
Routes of
administration		Intravenous infusion
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)[1]
  • EU: Rx-only[2]
Identifiers
CAS Number
KEGG

Arginine/lysine, sold under the brand name Lysakare, is a fixed-dose combination medication used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide.[2] It contains L-arginine hydrochloride and L-lysine hydrochloride.[2]

The most common side effects include nausea and vomiting.[2] Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.[2] Side effects with arginine/lysine are usually mild or moderate.[2]

Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney.[2] Arginine and lysine interfere with the passage of lutetium (177Lu) oxodotreotide through these kidney tubules.[2] As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation.[2]

Arginine/lysine was approved for medical use in the European Union in July 2019.[2]

Medical uses

Arginine/lysine is indicated for reduction of renal radiation exposure during peptide receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.[2]

References

  1. ^ "Lysakare Summary of Product Characteristics (SmPC)". (emc). 2 May 2024. Retrieved 24 May 2024.
  2. ^ a b c d e f g h i j k "Lysakare EPAR". European Medicines Agency (EMA). 24 May 2019. Retrieved 22 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Arginine/lysine&oldid=1225400303"